4D Molecular Therapeutics (FDMT) Other Working Capital Changes (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Other Working Capital Changes of -$878000.0 for Q1 2026, down 6171.43% year-over-year from $14461.2 in Q1 2025, and down 141.14% quarter-over-quarter from $2.1 million in Q4 2025.
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) Other Working Capital Changes (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Other Working Capital Changes for 7 consecutive years, with -$878000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 6171.43% year-over-year to -$878000.0; the TTM figure through Mar 2026 stood at -$1.1 million (up 38.4% YoY), while the FY2025 annual figure was -$209000.0, up 87.34% from the prior year.
- Other Working Capital Changes fell to -$878000.0 in Q1 2026 per FDMT's latest filing, from $2.1 million in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $4.0 million in Q1 2026 and bottomed at -$2.7 million in Q3 2025.
- Historically, Other Working Capital Changes has averaged $369411.8 across 5 years, with a median of $565000.0 in 2023.
- On a YoY basis, Other Working Capital Changes climbed as much as 224.07% in 2025 and fell as far as 77033.33% in 2025.
- 4D Molecular Therapeutics' Other Working Capital Changes stood at -$1.2 million in 2022, then jumped by 42.39% to -$719000.0 in 2023, then plunged by 139.22% to -$1.7 million in 2024, then surged by 224.07% to $2.1 million in 2025, then plunged by 141.14% to -$878000.0 in 2026.
- Business Quant data shows FDMT's Other Working Capital Changes at -$878000.0 in Q1 2026, $2.1 million in Q4 2025, and -$2.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 830,000.00 |
| Jun 30, 2026 | 830,000.00 |
| Mar 31, 2026 | 1.38 Mn |
| Mar 31, 2026 | 1.38 Mn |
| Dec 31, 2025 | -90,000.00 |
| Dec 31, 2025 | -90,000.00 |
| Sep 30, 2025 | -90,000.00 |
| Sep 30, 2025 | -90,000.00 |
| Jun 30, 2025 | -15,000.00 |
| Jun 30, 2025 | -15,000.00 |
| Mar 31, 2025 | -14,000.00 |
| Mar 31, 2025 | -14,000.00 |
| Sep 30, 2024 | -3,000.00 |
| Sep 30, 2024 | -3,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Mar 31, 2024 | 77,000.00 |
| Mar 31, 2024 | 77,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Dec 31, 2023 | 19,000.00 |